Histamine and indirect bronchoprovocation with adenosine monophosphate in asthma  by Lee, Daniel K.C. et al.
ARTICLE IN PRESSRespiratory Medicine (2005) 99, 5150954-6111/$ - s
doi:10.1016/j.r
DOI of origiLETTER TO THE EDITORHistamine and indirect bronchoprovocation with
adenosine monophosphate in asthma
Bucchioni and colleagues1 examined the concen-
trations of cysteinyl-leukotrienes and histamine in
exhaled breath condensate following bronchopro-
vocation with methacholine and adenosine mono-
phosphate in healthy controls and asthmatic
patients. Although the findings showing the lack
of change in either histamine or cysteinyl-leuko-
trienes concentrations in breath condensate fol-
lowing methacholine bronchial challenge was not
surprising, the absence of an increase in histamine
concentration following adenosine monophosphate
challenge was unexpected. Methacholine acts
directly on airway smooth muscle cells leading to
bronchoconstriction whereas adenosine monopho-
sphate acts indirectly on surface A2-purinoceptors
on primed mast cells triggering the release of pro-
inflammatory mediators such as prostaglandins,
cysteinyl-leukotrienes and histamine.
Modern histamine H1-receptor antagonists such
as desloratadine, fexofenadine, and levocetirizine
at clinically recommended doses as either mono-
therapy or add-on therapy to inhaled corticoster-
oids have been shown to attenuate bronchial
hyperresponsiveness leading to significant improve-
ment in the provocative concentration of adenosine
monophosphate causing a 20% fall in forced
expiratory volume in 1 s compared to placebo.2–4
Therefore, although the study serve to strength-
en the fact that adenosine monophosphate acts
indirectly by releasing cysteinyl-leukotrienes from
primed mast cells, the findings of the authors
should not be interpreted as casting doubt as to the
involvement of histamine in mediating the response
following indirect bronchial challenge testing. Theee front matter & 2004 Elsevier Ltd. All rights reserv
med.2004.09.004
nal article 10.1016/j.rmed.2004.09.003study should thus act as a catalyst for future
research into this area rather than providing
definitive proof of mediators involved in the
response following both direct and indirect bron-
chial challenges.References
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